1616113-45-1
Chemical Structure
Sibofimloc
Synonym(s): Antibiotic-202
- CAS No.: 1616113-45-1
- Formula:C35H39NO11
- Molecular Weight:649.68
IUPAC Name: 1-(2,7-bis(((2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)ethynyl)spiro[fluorene-9,4'-piperidin]-1'-yl)ethan-1-one
InChIKey: SFHMWDMKUYVSQJ-VECBPBMLSA-N
SMILES: CC(N(CC1)CCC21C3=CC(C#C[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=CC=C3C5=CC=C(C#C[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)C=C52)=O
Biological Activity: Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sibofimloc | 99.70% | Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sibofimloc (Standard) | ≥98% | Sibofimloc (Standard) is the analytical standard of Sibofimloc. This product is intended for research and analytical applications. Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ramtohul, Yeeman K, et al. Preparation of mannose derivatives via coupling and click cycloaddition reactions for treating bacterial infections. From PCT Int. Appl. (2014), WO 2014100158 A1 20140626.
- [2]. W Reinisch, et al. P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD), Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020: S479–S480.
Keywords
